Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>=18 and \</= 65 years of age~* HBeAg positive chronic hepatitis B~* Pre-treatment with entecavir for 9-36 months~Exclusion Criteria:~* Antiviral, antineoplastic or immunomodulatory treatment~* Co-infection with active hepatitis A, C or D, or HIV~* Evidence of decompensated liver disease~* History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Peginterferon alfa-2a + entecavir (Type: EXPERIMENTAL): Participants received PEGASYS® (peginterferon alfa-2a)180 micrograms (mcg) subcutaneously once weekly for 48 weeks, plus entecavir 0.5 milligram (mg) orally once daily for 8 weeks.
- Entecavir (Type: ACTIVE_COMPARATOR): Participants received entecavir 0.5 mg orally once daily for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).